When Four Organisations Publish Joint Guidance, It Is Not Just Good Practice: It Is an Admission

Four leading American health organisations have published joint guidance on nutritional priorities for GLP-1 therapy. Competing bodies do not typically collaborate this way. From an educational perspective, this signals a workforce preparation gap that traditional medical training failed to address. The guidance itself is sound. The fact it needed to be written at all is the real story.

by Nigel Hinchliffe, CCH Director of Education

What the Guidance Reveals

The joint clinical advisory “Nutritional priorities to support GLP-1 therapy for obesity” from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society (Mozaffarian et al., 2025) outlines eight clinical priorities: baseline nutritional assessment, personalised nutrition plans, micronutrient monitoring, adequate protein intake with strength training, and support for broader lifestyle change. These are sensible clinical recommendations that should already be standard practice.

That competing professional bodies felt compelled to collaborate and publish such guidance is significant. This is not routine. When organisations pool resources and authority in this way, it signals something more fundamental than best practice. It signals a gap that traditional training structures have failed to address.

The Prescription Outpaced the Preparation

GLP-1 prescribing has surged globally. In the UK, as elsewhere, these medications have moved from diabetes management to mainstream obesity treatment with remarkable speed. The medications work: that is not in question. Weight loss averages 15-25% over one year. For many patients, these drugs represent the first treatment that produces meaningful, sustained results.

But beneath those headline numbers sits a more complex reality:

When GLP-1 medications are discontinued, up to two-thirds of lost weight returns within one year, even with continuing lifestyle intervention (Wilding et al., 2022). Discontinuation is not rare: more than half of patients stop treatment within twelve months (Wilding et al., 2025).

Lean body mass can account for 15-40% of total weight loss, raising legitimate concerns about muscle preservation, particularly in older adults (Neeland et al., 2024).

Many patients initiating GLP-1 therapy already present with nutritional deficiencies related to previous dietary patterns, which appetite-suppressing medications can compound if intake is not carefully monitored.

These are not theoretical risks. They are predictable consequences of deploying effective pharmacotherapy without adequately preparing the workforce to manage the broader clinical picture.

Where the Training System Failed

Traditional medical education trains practitioners to prescribe medications. It does not systematically prepare them to integrate pharmacotherapy within comprehensive obesity care models.

Consider what is actually required to use GLP-1 medications well:

• Nutritional competence to assess baseline status, monitor micronutrients, and guide adequate protein intake
• Exercise physiology knowledge to recommend resistance training protocols that preserve lean mass
• Behaviour change skills to support patients through appetite suppression, side-effect management, and long-term adherence
• Clinical judgment to identify which patients are appropriate candidates and when to adjust or discontinue treatment

Most prescribers received minimal training in obesity management during their medical education. Many have no formal training in nutrition science or behaviour change. The expectation that they will seamlessly integrate these competencies whilst managing existing clinical workloads is unrealistic.

That is the gap this joint guidance exposes. Four organisations had to collaborate to publish what amounts to a remedial curriculum, not because practitioners are not capable, but because the training infrastructure never equipped them for this role in the first place.

What UK Healthcare Can Learn

The guidance originates from American organisations, but the implications are universal. GLP-1 mechanisms, clinical challenges, and workforce preparation gaps do not respect healthcare system boundaries.

The UK has an opportunity to address this more systematically:

Acknowledge the competency gap openly The NHS already recognises that obesity care requires specific competencies. The College of Contemporary Health developed comprehensive obesity care competencies for UK healthcare education, emphasising that practitioners should:

• Use patient-centric techniques for shared decision-making
• Apply integrated knowledge of nutrition, physical activity, behavioural interventions and pharmacotherapy
• Work collaboratively within interdisciplinary teams (Capehorn et al., 2022)

The American guidance validates these competencies. The question is whether UK healthcare will invest in developing them systematically or continue expecting practitioners to acquire them informally.

Provide structured professional development All healthcare professionals supporting patients on GLP-1 therapy (not just prescribers) benefit from understanding these medications’ mechanisms, metabolic effects, and integration with nutrition and lifestyle factors. This includes practice nurses, dietitians, physiotherapists, health coaches, and pharmacists.

CCH’s two-hour online course, GLP-1 RAs in Focus: Why Drugs Like Ozempic Work, offers accessible professional development for any healthcare role involved in supporting these patients. But single courses are not sufficient. What is needed is embedded professional development across training programmes, with nutrition and behaviour change integrated into core curricula rather than treated as optional add-ons.

Build multidisciplinary infrastructure The American guidance emphasises that no single practitioner holds all necessary expertise. Effective obesity care requires coordinated, multidisciplinary practice. Yet many UK healthcare settings lack the infrastructure for dietitians, psychologists, physiotherapists and prescribers to work collaboratively on obesity management.

Building this infrastructure demands investment, not just in individual competencies but in systems that enable effective teamwork.

The Broader Pattern

This is not unique to GLP-1 therapy. It is the pattern of how healthcare education responds to clinical innovation: slowly, incompletely, and only after gaps become too conspicuous to ignore.

We see it repeatedly. New treatments emerge. Evidence accumulates. Clinical practice evolves. And training structures lag behind, leaving practitioners to bridge the gap through self-directed learning, on-the-job experience, and eventual remedial guidance like this joint advisory.

The question is not whether GLP-1 medications are valuable (they demonstrably are). The question is whether we are prepared to support the people using them, and whether we will build that preparation into training systems or continue addressing it retrospectively through joint guidance documents.

For the organisations that published this advisory, the answer was clear: the gap had grown too large to leave unaddressed. That they felt compelled to collaborate across professional boundaries to address it tells us everything we need to know about the scale of the challenge.

Useful Resources

• Mozaffarian D et al. (2025) Nutritional priorities to support GLP-1 therapy for obesity
• CCH online short course: GLP-1RAs in Focus – Why Drugs Like Ozempic Work
• CCH online short course: Behaviour Change Skills – Complete Package
• Capehorn MS et al. (2022) UK obesity care competencies

About the Author

This article was written by Nigel Hinchliffe, Director of Education at the College of Contemporary Health (CCH). Nigel has extensive experience in clinical education, with a particular focus on obesity care and the safe integration of new therapies into practice. At CCH, he leads the development of evidence-based training programmes that support healthcare professionals in delivering high-quality, patient-centred care.


Click below for References

Capehorn, M.S., Hinchliffe, N., Cook, D., Hill, A., O’Kane, M., Tahrani, A.A., Vincent, A., Williams, S. and Feenie, J. (2022) ‘Recommendations from a working group on obesity care competencies for healthcare education in the UK: a report by the steering committee’, Advances in Therapy, 39, pp. 3019-3030.

Mozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C.M., Bindlish, S., Bonnet, J., Butsch, W.S., Christensen, S., Gianos, E., Gulati, M., Gupta, A., Horn, D., Kane, R.M., Saluja, J., Sannidhi, D., Stanford, F.C. and Callahan, E.A. (2025) ‘Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society’, Obesity, 33, pp. 1475-1503.

Neeland, I.J., Lim, S., Tchang, B.G., Gastaldelli, A., Rangel Soares, A.L., Mundi, M.S., Hocking, S.L., Janez, A. and Pozzilli, P. (2024) ‘Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies’, Diabetes, Obesity and Metabolism, 26(10), pp. 4363-4379.

Wilding, J.P.H., Batterham, R.L., Davies, M., Van Gaal, L.F., Kandler, K., Konakli, K., Lingvay, I., McGowan, B.M., Oral, T.K., Rosenstock, J., Wadden, T.A., Wharton, S., Yokote, K. and Kushner, R.F. (2022) ‘Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension’, Diabetes, Obesity and Metabolism, 24(8), pp. 1553-1564.

Wilding, J.P.H., Batterham, R.L., Fujioka, K., Kataoka, M., MacNeil, D.J., Rubino, D., Christensen, R., Jensen, C.B. and Wadden, T.A. (2025) ‘Discontinuation and reinitiation of dual-labeled GLP-1 receptor agonists among US adults with overweight or obesity’, JAMA Network Open, 8(1), e2429779.